GenOway
A global biotechnology company dedicated to the development and commercialization of unique, innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research.
Launch date
Employees
Market cap
AUD54.8m
Enterprise valuation
AUD60m (Public information from Sep 2024)
Share price
€3.72 ALGEN.PA
Company register number 422123125
Lyon Auvergne-Rhône-Alpes (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 10.0m | 10.0m | 9.5m | 11.0m | 14.0m | 17.1m | 20.0m |
| % growth | - | - | (5 %) | 16 % | 27 % | 22 % | 18 % |
| EBITDA | 1.0m | 1.0m | <1m | <1m | 1.5m | 3.3m | 6.0m |
| % EBITDA margin | 10 % | 10 % | 4 % | 9 % | 11 % | 19 % | 30 % |
| Profit | - | - | (1.0m) | (<1m) | (<1m) | <1m | 1.6m |
| % profit margin | - | - | (11 %) | (6 %) | (2 %) | 5 % | 8 % |
| EV / revenue | 1.2x | 1.4x | 1.3x | 2.7x | 3.1x | 2.3x | 2.2x |
| EV / EBITDA | 11.7x | 14.2x | 31.8x | 31.4x | 29.1x | 12.1x | 7.3x |
| R&D budget | 7.0m | 8.0m | 10.0m | 7.0m | - | - | - |
| R&D % of revenue | 70 % | 80 % | 106 % | 64 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
€60.0k | Grant | ||
| N/A | €5.6m | Private Placement VC | |
| Total Funding | AUD9.6m | ||
